Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
A clinical-stage biopharmaceutical company developing and commercializing late-stage neurological therapies for Asia-Pacific.
BioShin is a clinical-stage biopharmaceutical company based in Shanghai, China, that develops and commercializes targeted neurological and psychiatric medicines specifically tailored for the Asia-Pacific market. The organization focuses on advancing late-stage neuroscience therapies, primarily targeting conditions such as acute migraines and spinocerebellar ataxias through licensed clinical assets like rimegepant and trigriluzole. Operating across regional markets including China, South Korea, Australia, and New Zealand, the firm advances its clinical portfolio through rigorous late-stage trials and regulatory submissions. To support these regional clinical trials and commercialization efforts, the enterprise successfully raised $60 million in a Series A financing round. This capital injection was backed by a syndicate of prominent institutional investors including OrbiMed, Cormorant Asset Management, and HBM Healthcare Investments. BioShin was founded in 2018 as a dedicated regional subsidiary by its parent organization, Biohaven Pharmaceuticals.
BioShin has raised $60.0M across 1 funding round.
BioShin has raised $60.0M in total across 1 funding round.
BioShin has raised $60.0M across 1 funding round. Most recently, it raised $60.0M Series A in September 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 28, 2020 | $60M Series A | David Wang | Cormorant Asset Management, HBM Healthcare Investments, Surveyor Capital, Suvretta Capital Management | Announced |
BioShin has raised $60.0M in total across 1 funding round.
BioShin's investors include David Wang, Cormorant Asset Management, HBM Healthcare Investments, Surveyor Capital, Suvretta Capital Management.